Current Status of G-CSF Based Stem Cell Therapy for Patients with Myocardial Infarction.
- Author:
Hyun Jae KANG
1
;
Hyo Soo KIM
Author Information
1. Cardiovascular Center, Seoul National University Hospital, Seoul, Korea. hyosoo@snu.ac.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Myocardial infarction;
Stem cell;
Peripheral blood;
G-CSF
- MeSH:
Bone Marrow;
Granulocyte Colony-Stimulating Factor*;
Humans;
Myocardial Infarction*;
Myocytes, Cardiac;
Stem Cells*
- From:Hanyang Medical Reviews
2006;26(2):69-74
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Stem cell therapy using mobilized peripheral blood stem cells with G-CSF is considered a promising alternative of bone marrow stem cell therapy. G-CSF based therapy has many advantages compared to stem cell therapy using bone marrow stem cells, including noninvasiveness and direct protective effects on cardiomyocytes. Results from clinical trials using G-CSF mobilization alone showed mixed outcomes. However, additional intra-coronary infusion of mobilized stem cell by G-CSF showed better and consistent improvement in outcomes than G-CSF mobilization alone. Safety concerns about G-CSF raised by earlier clinical trials, such as aggravation of restenosis, were mostly resolved by recent clinical trials. However, long term safety and efficacy of stem cell therapy should be carefully evaluated by further studies. Current efficacy of stem cell therapy should be improved by tailored therapy for individual patients and optimized by modification of current stem cell therapy.
